What is AblaCare?
AblaCare is a health technology company dedicated to developing a novel treatment for Polycystic Ovary Syndrome (PCOS) known as Ovarian Rebalancing. This investigational therapy aims to restore ovulation through targeted ovarian ablation, offering a hormone-free, outpatient solution. The company is currently advancing through clinical trials, with the objective of obtaining FDA approval in the United States and a CE Mark in Europe to bring this treatment to patients suffering from PCOS.
How much funding has AblaCare raised?
AblaCare has raised a total of $8.1M across 1 funding round:
Series A
$8.1M
Series A (2019): $8.1M with participation from Sofinnova Partners
Key Investors in AblaCare
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact the company's collective future.
What's next for AblaCare?
With the recent major strategic investment, AblaCare is poised for significant expansion. The capital infusion is expected to accelerate the company's path toward regulatory approvals in key markets, including the US and Europe. This funding will likely support further clinical development, manufacturing scale-up, and the establishment of commercial operations, positioning AblaCare to address a substantial unmet need in women's reproductive health.
See full AblaCare company page
